

# Somatically acquired *JAK1* mutations in adult acute lymphoblastic leukemia

Elisabetta Flex,<sup>1</sup> Valentina Petrangeli,<sup>1</sup> Lorenzo Stella,<sup>3</sup> Sabina Chiaretti,<sup>4</sup> Tekla Hornakova,<sup>5</sup> Laurent Knoops,<sup>5</sup> Cristina Ariola,<sup>4</sup> Valentina Fodale,<sup>1</sup> Emmanuelle Clappier,<sup>6</sup> Francesca Paoloni,<sup>7</sup> Simone Martinelli,<sup>1</sup> Alessandra Fragale,<sup>2</sup> Massimo Sanchez,<sup>1</sup> Simona Tavolaro,<sup>4</sup> Monica Messina,<sup>4</sup> Giovanni Cazzaniga,<sup>8</sup> Andrea Camera,<sup>9</sup> Giovanni Pizzolo,<sup>10</sup> Assunta Tornesello,<sup>11</sup> Marco Vignetti,<sup>4</sup> Angela Battistini,<sup>2</sup> Hélène Cavé,<sup>6</sup> Bruce D. Gelb,<sup>12</sup> Jean-Christophe Renault,<sup>5</sup> Andrea Biondi,<sup>8</sup> Stefan N. Constantinescu,<sup>5</sup> Robin Foà,<sup>4</sup> and Marco Tartaglia<sup>1</sup>

<sup>1</sup>Dipartimento di Biologia Cellulare e Neuroscienze, <sup>2</sup>Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanità, Rome, 00161, Italy

<sup>3</sup>Dipartimento di Scienze e Tecnologie Chimiche, Università "Tor Vergata," Rome, 00133, Italy

<sup>4</sup>Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza," Rome, 00161, Italy

<sup>5</sup>Ludwig Institute for Cancer Research and de Duve Institute, Université Catholique de Louvain, Bruxelles, B1200, Belgium

<sup>6</sup>Département de Génétique, Hôpital Robert Debré, Paris, 75019, France

<sup>7</sup>Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Data Center, GIMEMA Foundation, Rome, 00161, Italy

<sup>8</sup>Centro Ricerca M. Tettamanti, Clinica Pediatrica Università di Milano Bicocca, Monza, 20052, Italy

<sup>9</sup>Dipartimento di Medicina Clinica e Sperimentale, Università "Federico II," Napoli, 80131, Italy

<sup>10</sup>Divisione di Ematologia, Università degli Studi di Verona, Verona, 37100, Italy

<sup>11</sup>Divisione di Oncologia Pediatrica, Università Cattolica del Sacro Cuore, Rome, 00100, Italy

<sup>12</sup>Departments of Pediatrics and Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029

**Aberrant signal transduction contributes substantially to leukemogenesis. The *Janus kinase 1 (JAK1)* gene encodes a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors and plays a nonredundant role in lymphoid cell precursor proliferation, survival, and differentiation. We report that somatic mutations in *JAK1* occur in individuals with acute lymphoblastic leukemia (ALL). *JAK1* mutations were more prevalent among adult subjects with the T cell precursor ALL, where they accounted for 18% of cases, and were associated with advanced age at diagnosis, poor response to therapy, and overall prognosis. All mutations were missense, and some were predicted to destabilize interdomain interactions controlling the activity of the kinase. Three mutations that were studied promoted *JAK1* gain of function and conferred interleukin (IL)-3-independent growth in Ba/F3 cells and/or IL-9-independent resistance to dexamethasone-induced apoptosis in T cell lymphoma BW5147 cells. Such effects were associated with variably enhanced activation of multiple downstream signaling pathways. Leukemic cells with mutated *JAK1* alleles shared a gene expression signature characterized by transcriptional up-regulation of genes positively controlled by JAK signaling. Our findings implicate dys-regulated *JAK1* function in ALL, particularly of T cell origin, and point to this kinase as a target for the development of novel antileukemic drugs.**

## CORRESPONDENCE

Marco Tartaglia:  
mtartaglia@iss.it

Abbreviations used: ALL, acute lymphoblastic leukemia; B-ALL, B cell precursor ALL; CM, conditional medium; DFS, disease-free survival; DHPLC, denaturing HPLC; ERK, extracellular signal-regulated kinase; OS, overall survival; T-ALL, T cell ALL.

Acute lymphoblastic leukemia (ALL) comprises a biologically heterogeneous group of clonal disorders that originate from the uncontrolled proliferation and expansion of immature lymphoblastic cells and are characterized by an ex-

tremely variable clinical outcome (1, 2). In recent years, substantial progress has been made toward understanding the molecular events contributing to malignant transformation. This has permitted the recognition of relevant prognostic factors and risk stratification, and has favored the implementation of therapeutic approaches based on cytogenetic and molecular lesions (2–5). Despite

E. Flex and V. Petrangeli contributed equally to this paper.  
The online version of this article contains supplemental material.

these accomplishments, long-term survival in adults with ALL remains largely unsatisfactory, making the design of novel antileukemic drugs tailored to specific biological targets a current priority (4, 6).

The four mammalian members of the JAK family (JAK1, JAK2, JAK3, and TYK2) are nonreceptor tyrosine kinases functioning as signal transducers to control cellular proliferation, survival, and differentiation (7, 8). JAK proteins associate constitutively with a variety of cytokine receptors lacking intrinsic kinase activity, and promote signal flow by phosphorylating tyrosyl residues of activated receptors to allow the recruitment and activation of STAT proteins. They share a complex multidomain structure characterized by a tyrosine kinase domain at the C terminus, which is flanked by a catalytically inactive pseudokinase domain with regulatory function. Their N-terminal half contains a FERM homology domain, which is implicated in receptor binding and possibly regulates the catalytic activity of the kinase, and an adjacent SH2-like domain. In contrast to their conserved structure, increasing experimental data indicate that JAK family members preferentially associate with a diverse subset of cytokine receptors, each differentially expressed by individual cell lineages and tissues, facilitating specificity in function (9). Among them, JAK1 plays an essential and nonredundant role in mediating biological responses induced by a specific subgroup of cytokines controlling lymphoid cell precursor development (10). *Jak1*<sup>-/-</sup> mouse pups exhibit a thymus that is markedly reduced in size, which is associated with a severe decrease in cellularity. *Jak1* loss of function is also associated with profound abnormalities in the B cell compartment caused by a block in differentiation at the pro-B/pre-B cell transition step, resulting in a deficit in the production of mature B lymphocytes (10). Based on its crucial role in lymphocyte proliferation, survival, and differentiation, we hypothesized that up-regulation of JAK1 signaling might contribute to malignancies of the lymphoid lineage. In this study, we report that somatic activating *JAK1* mutations occur among adults with T cell precursors ALL, and are associated with poor response to therapy and overall prognosis.

## RESULTS AND DISCUSSION

### *JAK1* mutation analysis in ALL

To explore possible contributions of somatic *JAK1* gene mutations in ALL, genomic DNA samples from BM aspirates of adult subjects with B cell precursor ALL (B-ALL; *n* = 88) and T cell ALL (T-ALL; *n* = 38) obtained at diagnosis and before therapy were screened for mutations in the entire *JAK1* coding region using denaturing HPLC (DHPLC). Direct sequencing of variant elution profiles allowed the identification of 37 intronic and exonic changes, including 9 nonsynonymous variants observed in 14 individuals (Table I and Table S1, available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>). Among the missense defects, genotyping of genomic DNAs from BM obtained during remission demonstrated the somatic origin of the 1535C>T (Ser512Leu), 1901C>A (Ala634Asp), and 2171G>A (Arg724His) changes in the leukemic clones

(Fig. 1 A and Table I). To verify that the nonsynonymous substitutions identified in patients for whom nonleukemic DNA was not available were not gene variants occurring in the population, 335 population-matching control individuals were analyzed, and none harbored the 611A>T (Lys204Met), 2635C>A (Arg879Ser), 2635C>T (Arg879Cys), and 2636G>A (Arg879His) changes or other defects altering those codons. Although the T-ALL-restricted occurrence of three distinct substitutions affecting Arg<sup>879</sup> (3/38 versus 0/335; Fisher's exact probability < 0.001) further supported the relevance of the substitution of this residue, we could not exclude that the 611A>T change might represent a private neutral variant. The two remaining missense changes, 184A>G (Ile62Val) and 1078C>T (Arg360Trp), were deemed nonpathogenic variants, as they were observed in nonleukemic cells of affected patients or in unaffected control subjects.

All mutations occurred as heterozygous changes and affected conserved residues within the FERM, SH2, pseudokinase, and kinase domains (Fig. 1 B). In two cases, DHPLC profiles and electropherograms indicated that the mutant allele might be present in only a fraction of leukemic cells, suggesting that these lesions did not represent early events during leukemogenesis but were acquired during disease progression (Fig. 1 C). Remarkably, mutations were relatively common among individuals with T-ALL (18.4% of cases, 95% CI = 7.7–34.3%), whereas they occurred in only three patients with B-ALL (3.4% of cases, 95% CI = 0.7–9.6%; Table I). Such a difference in mutation prevalence between cohorts was statistically significant (Fisher's exact probability = 0.003). DHPLC screening performed on affected exons by using pooled DNAs excluded loss of the normal allele and a homozygous condition for a gene variant caused by mitotic recombination in all cases.

To investigate the prevalence of *JAK1* mutations among pediatric ALL cases, genomic DNA from BM obtained at diagnosis was scanned for mutations in affected exons. No lesion was observed within the B-ALL cohort (*n* = 85), whereas a nonsynonymous 1957C>T transition (Leu653Phe) was identified in 1 of 49 subjects with T-ALL (2.0% of cases, 95% CI = 0.05–10.9%). This mutation was not observed in the BM obtained from the patient at the time of remission, indicating that it was somatically acquired in the leukemic cells.

Overall, these results indicated that *JAK1* gene mutations occur in ALL and are more frequently observed among adult individuals with involvement of the T cell lineage.

### Functional consequences of somatic *JAK1* mutations

To examine the effects of the identified mutations on protein function, WT *JAK1* or a mutant form (A634D, R724H, and R879C) was expressed transiently in *JAK1*-defective human fibrosarcoma U4C cells, and endogenous STAT1 phosphorylation was compared basally and after stimulation with IFN- $\gamma$  (Fig. 2 A). Consistent with previous studies (10, 11), untransfected cells lacking functional *JAK1* did not exhibit STAT1 phosphorylation in response to IFN- $\gamma$ . All *JAK1* mutants promoted an enhanced response to the ligand compared with

**Table I.** List of nonsynonymous *JAK1* changes identified in subjects with ALL

Cohort and lineage	Number of cases	Nucleotide substitution	Exon	Amino acid substitution	Domain	Mutation/polymorphism
Adult ALL						
B-ALL						
	88					
	1	184A>G	2	Ile62Val	FERM	Polymorphism <sup>a</sup>
	1	611A>T	5	Lys204Met	FERM	Mutation <sup>b</sup>
	1	1901C>A	13	Ala634Asp	Pseudokinase	Mutation
	1	2171G>A	15	Arg724His	Pseudokinase	Mutation <sup>d</sup>
T-ALL						
	38					
	1	184A>G	2	Ile62Val	FERM	Polymorphism <sup>a</sup>
	1	1078C>T	7	Arg360Trp	FERM	Polymorphism <sup>c</sup>
	1	1535C>T	10	Ser512Leu	SH2	Mutation <sup>d</sup>
	1	1901C>A	13	Ala634Asp	Pseudokinase	Mutation <sup>d</sup>
	3	2171G>A	15	Arg724His	Pseudokinase	Mutation <sup>e</sup>
	1	2635C>A	18	Arg879Ser	Kinase	Mutation <sup>b,f</sup>
	1	2635C>T	18	Arg879Cys	Kinase	Mutation <sup>b</sup>
	1	2636G>A	18	Arg879His	Kinase	Mutation <sup>b</sup>
Childhood ALL						
B-ALL						
	85					
T-ALL						
	49					
	1	1957C>T	13	Leu653Phe	Pseudokinase	Mutation <sup>d</sup>

<sup>a</sup>This change was observed in unaffected individuals.

<sup>b</sup>This change was not present among 335 population-matching control individuals.

<sup>c</sup>This change was present at remission.

<sup>d</sup>This change was not present at remission.

<sup>e</sup>This change was not present at remission in the one individual analyzed.


<sup>f</sup>This subject carried a concomitant 2171G→A change.

WT *JAK1*. Of note, basal STAT1 phosphorylation was observed in cells expressing the A634D mutant, suggesting ligand-independent up-regulation of the kinase. Consistent with this, expression of the A634D mutant resulted in an essentially constitutive STAT1 transcriptional activation, whereas a statistically significant increase in STAT1 activity was observed in U4C cells expressing both the R724H and R879C mutants, basally and after stimulation (Fig. 2 B).

To further assess the ability of mutations to up-regulate signal flow, we transduced Ba/F3 cells with WT *Jak1* or each of the selected mutants to evaluate whether their expression induced autonomous growth of cytokine-dependent cells. GFP-expressing Ba/F3 cells were selected by flow cytometry, cultured in 5 or 0.5% WEHI-3B cell conditional medium (CM) as a source of IL-3, as well as in absence of the cytokine, and counted to assess proliferation (Fig. 2 C). Three independent experiments indicated that expression of the A634D and, with less efficiency, R724H *Jak1* mutants conferred IL-3-independent growth to cells, whereas cells expressing WT *Jak1* or the R879C *Jak1* mutant retained dependence on the cytokine for survival. Of note, cells expressing each of the three mutants exhibited enhanced growth in response to IL-3. Consistent with these findings, Ba/F3 cells expressing the A634D *Jak1* mutant exhibited enhanced Stat5, Akt, and extracellular signal-regulated kinase (ERK) phosphorylation basally and after stimulation, whereas a higher phosphorylation level of these signal transducers in cells expressing the R724H

*Jak1* protein was observed in cultures maintained in the presence of IL-3 (Fig. 2 D). Notably, we did not observe *Jak1* phosphorylation in parental and transduced Ba/F3 cells basally and cultured in 2% WEHI-3B cell CM; however, phosphorylation was appreciable in A634D and R724H *Jak1*-transduced cells after selection (7-d culture in absence of IL-3; unpublished data).

IL-9 protects the T cell lymphoma BW5147 cell line against dexamethasone-induced apoptosis (12), an effect that is dependent on *Jak1*-mediated Stat3 and Stat5 activation (13). To demonstrate the activating role of the ALL-associated *JAK1* mutations in a different cellular system, BW5147 cells were transduced with WT *Jak1* or each of the selected mutants to evaluate their effect on this stress response. GFP-expressing cells were isolated by flow cytometry, cultured in the presence of cyclosporine A and dexamethasone, with or without IL-9, and [<sup>3</sup>H]thymidine incorporation was determined to assess proliferation (Fig. 2 E). Three independent experiments documented that expression of the A634D and R879C *Jak1* mutants, but not R724H *Jak1*, conferred increased growth to cells basally. Of note, whereas transduced cells exhibited comparable responses to high levels of IL-9, those expressing the A634D and R879C *Jak1* mutants were more responsive to low levels of the cytokine. Expression of the A634D *Jak1*, but not that of the R879C mutant, was associated with enhanced phosphorylation of *Jak1*, Stat3, and Stat5 basally (unpublished data).



**Figure 1. Somatic *JAK1* mutations in ALL.** (A) Representative electropherograms showing the occurrence of somatically acquired *JAK1* mutations in subjects with T-ALL. In all cases, mutations were observed at diagnosis (top), but were undetectable during remission (bottom). (B) *JAK1* domain structure and location of affected residues. The predicted amino acid substitutions resulting from the *JAK1* mutations are positioned below the diagram of the protein with its functional domains indicated (left) and shown in *JAK1* three-dimensional modeled structure (right). (C) Electropherograms showing the occurrence of mutations in a fraction of leukemic cells of two individuals with T-ALL. In both patients, the mutant allele constituted only a portion of the amplified fragment from BM obtained at diagnosis (blasts >70% of total cells; top). The heterozygous status of each subject for an intragenic polymorphic site (bottom) is shown for comparison.

Overall, these data indicated that the three selected leukemia-associated *JAK1* mutants are hypermorphs, with A634D *Jak1* having a seemingly stronger effect, and that different mechanisms are likely to be involved in their cell context-related gain of function.


### Molecular modeling of *JAK1* and location of affected residues

To look at the structural causes resulting in *JAK1* functional up-regulation, we generated a model of *JAK1* structure because no crystallographic information was available for this protein. Energy-minimized models of each of the four domains were generated separately by homology to available crystallographic structures of proteins with similar sequences and overall fold. The quaternary arrangement of the four domains was then determined by superimposing the models on a predicted three-dimensional structure of *JAK2* (14). According to the superimposed structure, Ala<sup>634</sup> and Leu<sup>653</sup> are placed on the surface of the pseudokinase domain involved in the interaction with the kinase domain (Fig. 1 B). Based on the evidence supporting a negative regulatory role of the pseudokinase domain on catalytic function of *JAK* proteins (15–17), the pathogenetic mechanism of the A634D and L653F changes is predicted to involve a looser interdomain interaction, relaxing inhibitory control on the kinase activity. Consistent with this hypothesis, substitution of two residues located in the pseudo-

kinase domain at the interface with the kinase domain in *JAK2* (Val<sup>617</sup>) and *JAK3* (Ala<sup>572</sup>) promote increased catalytic activity basally (Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>) (18–20). Our model also predicts that residues Lys<sup>204</sup> and Ser<sup>512</sup> would perturb the SH2–FERM interdomain interaction because they are located at the interface between these domains, approximately facing each other. This finding is noteworthy because it has been proposed that *JAK1*'s SH2 domain does not function as a phosphotyrosyl-binding domain, but instead plays a structural role in stabilizing the conformation of the FERM domain (21), which mediates its association to cytokine receptors and exerts an as yet uncharacterized restraint on catalytic function (22, 23). The molecular mechanism through which these mutations affect *JAK1* function remains to be explained. Structural and functional consequences were not obvious for the activating changes affecting residues Arg<sup>724</sup> and Arg<sup>879</sup>.

### Gene expression profile analysis in blasts with a mutated *JAK1* allele

Total RNA was available from blasts of 5 *JAK1* mutation-positive (S512L, A634D, and R724H) and 11 mutation-negative subjects of the T-ALL cohort. Unsupervised clustering based on 1,345 probe sets selected by nonspecific filtering clustered expression profiles of mutation-positive blasts into two clusters, suggesting contribution of *JAK1* mutations to



**Figure 2. Functional effects of leukemia-associated *JAK1* mutations.** (A) STAT1 phosphorylation assays. Basal and IFN- $\gamma$ -stimulated endogenous STAT1 phosphorylation in *JAK1*-defective U4C cells transiently transfected with WT *JAK1* or selected mutants. Blots are representative of three experiments. (B) STAT1 activation assays. Basal and IFN- $\gamma$ -stimulated endogenous STAT1 transcriptional activity in *JAK1*-defective U4C cells transiently cotransfected with p-GAS-Luc and pRL-TK constructs, and WT *JAK1* or a mutant allele. STAT1-induced luciferase gene expression levels were determined by measuring the luciferase activity (CPS, counts per second) normalized to the activity of the Renilla luciferase, using a dual-luciferase reporter assay system. Activity ratios are expressed as the mean of three replicates  $\pm$  the SD. (C) Ba/F3 survival assays. WT or mutant *Jak1*-transduced Ba/F3 cells were grown in the absence of IL-3 (top) or with 0.5% or 5% WEHI-3B cell CM as source of IL-3 (bottom). Cell numbers (mean of three replicates  $\pm$  the SD) were counted at the indicated time points (top) or at day 3 of culture (bottom). (D) Stat5, Akt, and ERK phosphorylation assays. Endogenous Stat5 Tyr694, Akt Ser473, and ERK1/2 Thr202/Tyr204 phosphorylation levels from lysates of Ba/F3 cells transduced with WT *Jak1* or a mutant form and cultured without IL-3 (left) or with 2% WEHI-3B cell CM as the source of IL-3 (right). Activation of Stat5 (pStat5/Stat5), AKT (pAkt/Akt), and ERK1/2 (pERK/ERK) is expressed as a multiple of activation in untransduced cells. Blots are representative of at least three experiments performed. (E) BW5147 proliferation assays. WT or mutant *Jak1* transduced BW5147 cells were grown in presence of 200  $\mu$ g/ml dexamethasone and 50  $\mu$ g/ml cyclosporine A, in absence (left) or with different concentrations (right) of IL-9. After 72 h, proliferation was measured after [ $^3$ H]thymidine added to the cultures (6 h). Data are shown as the means of three replicates  $\pm$  the SD. For convenience, the amino acid changes affecting residues Ala<sup>633</sup>, Arg<sup>723</sup>, and Arg<sup>878</sup> of the murine *Jak1* protein (encoded by the pMX-Jak1-IRES-GFP constructs used to transduce the Ba/F3 and BW5147 cell lines) are indicated according to the homologous residues in human *JAK1*.


distinct major mechanisms of deregulation (Fig. S2, available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>). Notably, supervised gene expression analysis revealed a distinctive expression signature shared by leukemic cells with a mutated *JAK1* gene (Fig. 3 A) based on the expression of 133 differentially expressed probe sets, consisting of 112 differentially expressed genes, the majority of them being over-expressed in *JAK1* mutation-positive samples (Table S2). Among the up-regulated genes, those whose transcription was

known to be positively modulated by JAK/STAT signaling, including *IRF1*, *SOCS3*, *ISG15*, *ISGF3G*, *IFI44L*, and *IRF7*, were overrepresented in all the *JAK1* mutation-positive subjects, further supporting the gain-of-function role of the ALL-associated *JAK1* lesions.

#### Clinical relevance of somatic *JAK1* mutations

The clinical relevance of *JAK1* mutations within the adult T-ALL cohort was investigated. Although no statistically

significant difference was observed in white blood cell counts, gender distribution, or association with specific chromosomal rearrangements, patients with a mutated *JAK1* allele tended to have a more advanced age at diagnosis (median = 40.6 vs. 24.2;  $P < 0.01$ ), which was consistent with the lower prevalence of mutations identified among children and adolescents with T-ALL included in the study. Comparison of the response to therapy between *JAK1* mutation-positive and -negative patients indicated a higher percentage of cases exhibiting resistance to induction therapy in the former (43 vs. 20%), although this difference did not reach statistical significance caused by the relatively small size of the study cohort. Consistent with that finding, a statistically significant reduced disease-free survival (DFS; median = 8.7 vs. 20.5 mo;  $P = 0.01$ ) and overall survival (OS; median = 10.6 vs. 32.5;  $P < 0.01$ ) was observed among *JAK1* mutation-positive patients (Fig. 3 B). Multivariate analysis confirmed the statistical



**Figure 3. Gene expression profiles and clinical relevance of somatic *JAK1* mutations in adult T-ALL.** (A) Supervised hierarchical clustering of gene expression profiles performed on blasts from 16 adult T-ALL patients, with (orange) or without (green) a *JAK1* mutation. (B) Kaplan-Meier estimates of DFS (top) and OS (bottom) in subjects with (red) or without (black) a *JAK1* mutation. Multivariate analysis confirmed the statistical significance of the reduced DFS and OS among *JAK1* mutation-positive patients, and excluded a significant contribution of the more advanced age of these subjects.

significance of these associations (DFS: HR = 6.20, 95% CI = 1.32–29.09,  $P = 0.02$ ; OS: HR = 2.82, 95% CI = 1.07–7.48,  $P = 0.04$ ), and excluded a significant contribution of patients' age (DFS: HR = 0.99, 95% CI = 0.93–1.05,  $P = 0.64$ ; OS: HR = 1.01, 95% CI = 0.97–1.05,  $P = 0.60$ ).

In the adult T-ALL cohort, the mutation status for *NRAS*, *KRAS*, *NOTCH1*, and *PTEN* was also assessed (unpublished data). Among the *JAK1* mutation-positive cases, no defect was observed in the *NRAS*, *KRAS*, and *PTEN* genes, although such mutations had a relatively low prevalence in the entire adult T-ALL cohort (*RAS* genes: 11% of cases, 95% CI = 2.9–24.8%; *PTEN*: 14% of cases, 95% CI = 4.5–28.8%). In contrast, heterozygous mutations in *NOTCH1* were observed in all *JAK1* mutation-positive individuals. Given the high prevalence of *NOTCH1* defects observed in the cohort (70% of cases, 95% CI = 53.0–84.1%), this association was not statistically significant ( $P = 0.06$ ). This observation, however, suggests that activation of *JAK1* and *NOTCH1* transduction pathways might cooperate in T-ALL pathogenesis and/or progression. No significant difference in response to therapy or outcome was observed between *NOTCH1* mutation-positive and -negative patients. Interestingly, *NOTCH1* and *PTEN* mutations exhibited a mutually exclusive distribution because none of the five subjects carrying *PTEN* lesions had a *NOTCH1* defect (Fisher's exact probability = 0.001).

#### Aberrant *JAK1* function and leukemogenesis

Functional up-regulation of two members of the JAK family, *JAK2* and *JAK3*, has recently been discovered in myeloproliferative disorders and other malignancies of the myeloid lineage (18–20, 24). The *JAK2* V617F amino acid change occurs in the majority of polycythemia vera cases and in ~50% of individuals with essential thrombocythemia or idiopathic myelofibrosis. The available data support the view that this recurrent change, which affects the pseudokinase domain of the protein, induces constitutive activation of the kinase and hypersensitivity to cytokines. Similarly, three *JAK3* hypermorphic alleles promoting cytokine independence in Ba/F3 cells have been identified in acute megakaryoblastic myeloid leukemia. In this study, we showed that somatically acquired activating *JAK1* mutations occur in ALL, particularly in adults, further emphasizing the importance of JAK-mediated signaling dysregulation in leukemogenesis and extending the spectrum of hematologic malignancies associated with aberrant activation of this signal transduction pathway. Even though the molecular mechanisms by which individual *JAK1* mutations promote gain of function are likely to be diverse and remain to be fully characterized, modeling and biochemical data are consistent with the view that, similar to what has been observed for somatic leukemia-associated *JAK2* and *JAK3* defects, most mutations would interfere with the autoinhibitory control on the catalytic activity. For most mutations, this effect would be achieved by triggering local structural rearrangements in regions involved in interdomain interactions between the

pseudokinase and kinase domains or the FERM and SH2 domains (Fig. S1).

JAK1 is expressed widely and participates in intracellular signaling elicited by class II cytokine receptors and receptors that use the gp130 or  $\gamma_c$  receptor subunit. Although the hematopoietic defects in *Jak1*<sup>-/-</sup> mice were restricted to the lymphoid cell compartment as a result of an impaired response to IL-7 (10) and the present findings indicate a cell-context dependence of somatically acquired *JAK1* mutations' contribution to leukemogenesis, we cannot exclude the involvement of this kinase in other malignancies. We speculate that a concomitant genetic event, including a mutation affecting other members of the JAK family, might synergize with the *JAK1* defect to promote aberrant cell proliferation and/or survival in a cell-specific context. This hypothesis is currently under investigation.

Although 70–80% of pediatric patients with either B- or T-ALL have excellent long-term response to intensive combination chemotherapy, adult patients exhibit a less favorable outcome (4, 25). In B- ALL, such a poor prognosis has been associated in part with the presence of *BCR/ABL* or *ALL1/AF4* gene rearrangements. In contrast, the unfavorable outcome of adult patients with T-ALL has not conclusively been attributed to any cytogenetic lesion, albeit the prognostic relevance of aberrant *ERG* and *TLX1* gene expression and *NOTCH1* mutations has recently been reported (26–28). The present work provides the first evidence that *JAK1* gene defects are associated with a poor response to therapy, frequent relapse of the disease, and reduced OS, identifying such mutations as a novel informative prognostic marker occurring in a sizable proportion of adult T-ALL. Although studies on larger cohorts are required to determine more precisely the clinical relevance and prognostic value of *JAK1* defects in adult and pediatric ALL, our findings provide a rationale for the development of novel therapeutic approaches tailored at interfering with JAK1 signaling, encouraging studies aimed at testing the efficacy and side effects of JAK1 inhibitors in the management of adult T-ALL patients.

## MATERIALS AND METHODS

**All cohorts and molecular analyses.** Cohorts studied included patients enrolled in the Gruppo Italiano Malattie Ematologiche dell'Adulto 0496 and 2000 (adults), and Associazione italiana ematologia ed oncologia pediatrica ALL 2000 (children and adolescents) clinical trials. Written informed consent for genetic analyses was obtained from all subjects according to the Declaration of Helsinki. BM mononuclear cells were isolated by density gradient centrifugation, and then cryopreserved. Genomic DNA was isolated in a standard fashion. Exons 26, 27, and 34 of the *NOTCH1* gene were analyzed by direct sequencing, whereas the entire *JAK1* and *PTEN* coding regions and exons 1 and 2 of *NRAS* and *KRAS* were screened by DHPLC (Wave 2100 System; Transgenomic) and sequencing. Primer sequences are available upon request. Gene expression profiling methodology is described in the Supplemental materials and methods (available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>).

**Functional studies.** The mutations resulting in the A634D, R724H, and R879C changes were introduced by site-directed mutagenesis in a VSV-

tagged *JAK1* cDNA cloned in pRc/CMV vector provided by S. Pellegrini (Pasteur Institute, Paris, France). *JAK1*-defective human fibrosarcoma U4C cells (provided by S. Pellegrini) were maintained in DME supplemented with 10% heat-inactivated FCS and antibiotics. To evaluate endogenous STAT1 phosphorylation, after starvation (24 h), transiently transfected cells were stimulated with IFN- $\gamma$  (1,000 U/ml, 15 min) or left unstimulated. Lysed samples were analyzed by 10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane (Pierce Chemical Co.) and probed with anti-phospho-Stat1 (9171; Cell Signaling Technology), anti-Stat1 (9172; Cell Signaling Technology), and anti-Jak1 (3332; Cell Signaling Technology) antibodies. Endogenous STAT1 transcriptional activity was assessed by luciferase transactivation assays in cells cotransfected with a p-GAS-Luc construct, switched to serum-starvation medium (8 h), and then stimulated with IFN- $\gamma$  (1,000 U/ml, 16 h) or left unstimulated. STAT1-induced luciferase expression was assessed and normalized using a dual luciferase reporter assay system (Promega) and a phRL-TK plasmid constitutively expressing the Renilla luciferase.

Each of the three leukemia-associated mutations was also introduced in the murine *Jak1* cDNA cloned in the bicistronic retroviral vector pMX-IRES-GFP. Constructs were transfected into Phoenix or BOSC packaging cells to produce retroviruses, and murine Ba/F3 (maintained in RPMI 1640 medium containing 10% FCS, 1% L-glutamine, and 10% WEHI-3B cell CM) and BW5147 (maintained in Iscove-Dulbecco's medium supplemented with 10% FBS, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 1.25 mM L-glutamine) cells were infected with retroviral supernatants. GFP-positive populations were purified by flow-cytometric sorting, and then expanded. Equal GFP expression levels of transduced cells were confirmed by FACS analysis (Fig. S3, available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>). Transduced Ba/F3 cells were cultured in the absence or presence of IL-3 (0.5 or 5% WEHI-3B cell CM) for assaying cytokine independence and response, and viable cells were counted by Trypan blue exclusion. Proliferation of transduced BW5147 cells cultured in the presence of 50  $\mu$ g/ml cyclosporine A and 200  $\mu$ g/ml dexamethasone, in the presence or absence of mL-9, was determined using [<sup>3</sup>H]thymidine incorporation assay. In brief, 3,000 cells were seeded in 96-well plates (200  $\mu$ l volume medium), and after 72 h, [<sup>3</sup>H]thymidine was added to the cultures for 6 h. Cells were then collected on microfilter plates, and thymidine incorporation was measured after addition of 25  $\mu$ l of liquid scintillant. For Western blot studies, Ba/F3 cells were starved in RPMI 1640 medium containing 1% BSA (5 h), and then stimulated with 2% WEHI-3B cell CM (30 min) or left unstimulated, whereas BW5147 cells were starved in Iscove-Dulbecco's medium (12 h) and left unstimulated or stimulated with 100 U/ml mL-9 for 15 min. Evaluation of Jak1, Akt, Stat3, Stat5, and ERK1/2 expression and phosphorylation levels was performed using anti-phospho-Jak1, anti-Jak1, anti-phospho-Akt, anti-Akt, anti-phospho-Stat3, anti-Stat3, anti-phospho-Stat5, anti-Stat5, anti-phospho-p44/42 ERK, and anti-p44/42 ERK antibodies (all from Cell Signaling Technology).

Structural models of the kinase, pseudokinase, and SH2 and FERM domains of JAK1 were generated as described in the online supplemental information section.

**Statistical analysis.** Confidence intervals of proportions (at 95% level) were calculated based on the binomial distribution. The probabilities of OS and DFS were estimated using the Kaplan-Meier method. The log-rank test was used to compare treatment effect and risk factor categories. All tests were two-sided, accepting  $P \leq 0.05$  as indicating a statistically significant difference. Cox proportional hazard models, including age and *JAK1* as variables, were used to perform multivariate analyses for OS and DFS. The SAS software (SAS Institute) was used for the analysis.

**Online supplemental material.** Methodologies and approaches used to generate the JAK1 molecular modeling and to perform and analyze adult T-ALL leukemic cell gene expression profiles (including cited references) are provided in the Supplemental Materials and methods. Table S1 is a list of the

intronic or synonymous *JAK1* changes identified in the study. Table S2 is a list of differentially expressed genes in *JAK1* mutation-positive versus mutation-negative adult subjects with T-ALL. Fig. S1 shows the JAK1 domain structure and the location of JAK1, JAK2, and JAK3 residues reported to be mutated in myeloproliferative disorders and leukemias. Fig. S2 shows the unsupervised hierarchical clustering of gene expression profiles of blasts from 16 adult T-ALL patients, with or without a *JAK1* mutation. Fig. S3 shows the GFP expression levels of purified Ba/F3 and BW5417 cells transduced with a bicistronic retroviral vector pMX-Jak1-IRES-GFP coding for WT Jak1 or one of the three generated mutants. The online version of this article is available at <http://www.jem.org/cgi/content/full/jem.20072182/DC1>.

We are indebted to the patients who participated in the study and physicians of the GIMEMA network who referred the subjects and provided BM specimens for the study. Thanks are due to Sandra Pellegrini (Pasteur Institute, Paris, France) for providing the JAK1-defective U4C cell line and the construct encoding the human VSV-tagged JAK1 protein, and Romano Kroemer (Sanofi-Aventis, Centre de Recherche de Paris, Vitry-sur-Seine, France) for making available the coordinates of the JAK2 model.

This work was supported by grants from Ricerca Oncologica Project of Integrated Program "Multidimensional classification of lymphohematopoietic malignancies" (to M. Tartaglia) and Associazione Italiana per la Ricerca sul Cancro (AIRC; to R. Foa). EF is supported by a fellowship from Associazione ONLUS "Morgan Di Gianvittorio per la cura e la ricerca nei tumori e leucemie in età pediatrica."

The authors declare no competing financial interests.

Submitted: 10 October 2007

Accepted: 4 March 2008

## REFERENCES

- Armstrong, S.A., and A.T. Look. 2005. Molecular genetics of acute lymphoblastic leukemia. *J. Clin. Oncol.* 23:6306–6315.
- Pui, C.H., and W.E. Evans. 2006. Treatment of acute lymphoblastic leukemia. *N. Engl. J. Med.* 354:166–178.
- Yeoh, E.J., M.E. Ross, S.A. Shurtleff, W.K. Williams, D. Patel, R. Mahfouz, F.G. Behm, S.C. Raimondi, M.V. Relling, A. Patel, et al. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell.* 1:133–143.
- Vitale, A., A. Guarini, S. Chiaretti, and R. Foa. 2006. The changing scene of adult acute lymphoblastic leukemia. *Curr. Opin. Oncol.* 18:652–659.
- Chiaretti, S., X. Li, R. Gentleman, A. Vitale, M. Vignetti, F. Mandelli, J. Ritz, and R. Foa. 2004. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. *Blood.* 103:2771–2778.
- Thomas, X. 2005. Emerging drugs for adult acute lymphoblastic leukaemia. *Expert Opin. Emerg. Drugs.* 10:591–617.
- Yamaoka, K., P. Saharinen, M. Pesu, V.E. Holt III, O. Silvennoinen, and J.J. O'Shea. 2004. The Janus kinases (Jaks). *Genome Biol.* 5:253.
- Schindler, C., D.E. Levy, and T. Decker. 2007. JAK-STAT signaling: from interferons to cytokines. *J. Biol. Chem.* 282:20059–20063.
- Murray, P.J. 2007. The JAK-STAT signalling pathway: Input and output integration. *J. Immunol.* 178:2623–2629.
- Rodig, S.J., M.A. Meraz, J.M. White, P.A. Lampe, J.K. Riley, C.D. Arthur, K.L. King, K.C. Sheehan, L. Yin, D. Pennica, et al. 1998. Disruption of the *Jak1* gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. *Cell.* 93:373–383.
- Müller, M., J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki, O. Silvennoinen, A. Harpur, G. Barbieri, B.A. Witthuhn, C. Schindler, S. Pellegrini, A.F. Wilks, J.N. Ihle, G.R. Stark, and L.M. Kerr. 1993. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. *Nature.* 366:129–135.
- Renauld, J.C., A. Vink, J. Louahed, and J. Van Snick. 1995. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. *Blood.* 85:1300–1305.
- Demoulin, J.B., C. Uyttenhove, E. Van Roost, B. DeLestre, D. Donckers, J. Van Snick, and J.C. Renauld. 1996. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. *Mol. Cell. Biol.* 16:4710–4716.
- Giordanetto, F., and R.T. Kroemer. 2002. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. *Protein Eng.* 15:727–737.
- Chen, M., A. Cheng, F. Candotti, Y.J. Zhou, A. Hymel, A. Fasth, L.D. Notarangelo, and J.J. O'Shea. 2000. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. *Mol. Cell. Biol.* 20:947–956.
- Lindauer, K., T. Loerting, K.R. Liedl, and R.T. Kroemer. 2001. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. *Protein Eng.* 14:27–37.
- Saharinen, P., and O. Silvennoinen. 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. *J. Biol. Chem.* 277:47954–47963.
- James, C., V. Ugo, J.P. Le Couedic, J. Staerk, F. Delhommeau, C. Lacout, L. Garcon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature.* 434:1144–1148.
- Levine, R.L., M. Wadleigh, J. Coombs, B.L. Ebert, G. Wernig, B.J. Huntly, T.J. Boggon, I. Wlodarska, J.J. Clark, S. Moore, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell.* 7:387–397.
- Walters, D.K., T. Mercher, T.L. Gu, T. O'Hare, J.W. Tyner, M. Loriaux, V.L. Goss, K.A. Lee, C.A. Eide, M.J. Wong, et al. 2006. Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell.* 10:65–75.
- Radtke, S., S. Haan, A. Jorissen, H.M. Hermanns, S. Diefenbach, T. Smyczek, H. Schmitz-Vandeleur, P.C. Heinrich, I. Behrmann, and C. Haan. 2005. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. *J. Biol. Chem.* 280:25760–25768.
- Haan, C., H. Is'harc, H.M. Hermanns, H. Schmitz-Van De Leur, I.M. Kerr, P.C. Heinrich, J. Grotzinger, and I. Behrmann. 2001. Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. *J. Biol. Chem.* 276:37451–37458.
- Zhou, Y.J., M. Chen, N.A. Cusack, L.H. Kimmel, K.S. Magnuson, J.G. Boyd, W. Lin, J.L. Roberts, A. Lengi, R.H. Buckley, et al. 2001. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. *Mol. Cell.* 8:959–969.
- Levine, R.L., M. Loriaux, B.J. Huntly, M.L. Loh, M. Beran, E. Stoffregen, R. Berger, J.J. Clark, S.G. Willis, K.T. Nguyen, et al. 2005. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. *Blood.* 106:3377–3379.
- Gokbuget, N., and D. Hoelzer. 2006. Treatment of adult acute lymphoblastic leukemia. *Hematology (Am Soc Hematol Educ Program).* 133–141.
- Baldus, C.D., T. Burmeister, P. Martus, S. Schwartz, N. Gokbuget, C.D. Bloomfield, D. Hoelzer, E. Thiel, and W.K. Hofmann. 2006. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. *J. Clin. Oncol.* 24:4714–4720.
- Ferrando, A.A., D.S. Neuberg, R.K. Dodge, E. Paietta, R.A. Larson, P.H. Wiernik, J.M. Rowe, M.A. Caligiuri, C.D. Bloomfield, and A.T. Look. 2004. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. *Lancet.* 363:535–536.
- Zhu, Y.M., W.L. Zhao, J.F. Fu, J.Y. Shi, Q. Pan, J. Hu, X.D. Gao, B. Chen, J.M. Li, S.M. Xiong, et al. 2006. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. *Clin. Cancer Res.* 12:3043–3049.